(Reuters) - Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches after the company found the treatment was unlikely to meet
Pharmaceutical companies are bracing themselves to answer a series of lawsuits filed by states, cities, and citizens accusing them of engaging in deceptive marketing that downplayed the risks of addiction
A Rockford, Illinois firefighter displays a dose of naloxone on July 14, 2017. Scott Olson—Getty Images Jamie Ducharme April 19, 2019 The Food and Drug Administration (FDA) on Friday announced that it
The U.S. Food and Drug Administration on Friday said it gave approval to Teva Pharmaceutical Industries Ltd. to market generic naloxone nasal spray to treat opioid overdoses. This is the first approval
cio.com - Martha Heller is CEO of Heller Search Associates, an IT executive recruiting firm specializing in CIO, CTO, CISO and senior technology roles in all industries. She is the author The CIO Paradox: Battling the Contradictions of IT Leadership and Be the Business: CIOs in the New Era of IT. To join the IT career conversation, subscribe to The Heller Report.